Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Functional effect of the Hsa-miR-185* on the <i>TrkB-T1</i> 3′UTR sequence in HEK 293 cell line. by Gilles Maussion (156014)

“…<p>A: Schematic representation of <i>TrkB-T1</i> 3′UTR sequence including the five putative binding sites for Hsa-miR-185*. …”

Relative abundance of bacterial families, for which statistically significant differences between the cohorts of IBS patients and healthy individuals (GreenGenes nomenclature). by V. Ivashkin (10960750)

Impact of precipitation and temperature changes on hydrological responses of small-scale catchments in the Ethiopian Highlands by Tatenda Lemann (3187935)

Comparison of 1D and 3D reservoir heat transport models and temperature effects on mass transport by Bruna Arcie Polli (10356390)

CFD simulation of cannabidiol delivery through microneedle patches by Liqun Shi (8309856)

Dirt on photovoltaic modules and efficient energy generation in the Brazilian semiarid by Tiago L. S. de Souza (12820142)

BIOCHEMICAL AND PIGMENT ANALYSIS ON PHYCOREMEDIATED MICROALGAL BIOMASS by G. k. Saravanan (515483)

Temperature influence on mobility and charge density model of photovoltaic cells by J.S.T. Souza (6380096)

Supplementary Material for: Cerebral Hemodynamic Failure Presenting as Limb-Shaking Transient Ischemic Attacks by Nedelmann M. (4127125)

Unexpected transient phenomena in positive lightning by Ziqin Ding (8470035)

HYS-32-Induced Microtubule Catastrophes in Rat Astrocytes Involves the PI3K-GSK3beta Signaling Pathway by Chi-Ting Chiu (734340)

“…Time-lapse experiments with immunoprecipitation further displayed that the association between EB-1 and β-tubulin was significantly decreased following a short-term treatment (2 h), but gradually increased in a prolonged treatment (6-24 h) with HYS-32. …”

Data Sheet 1_Spatiotemporal variability of turbulent fluxes in snow-covered mountain terrain.csv by Rainette Engbers (22611641)

“…Our findings indicate that while higher-resolution simulations improve agreement between measured and modeled variables, they tend to underestimate wind speeds (with a bias of up to 1.5 ± 0.2 m s−1), and turbulent fluxes (up to 14 ± 3.7 W m−2) and consequently lower snow surface temperatures (up to 3.3 ± 0.3 °C). …”